De Novo device
Dulbecco's Modified Eagle Medium (Dmem)
Life Technologies, Inc. · Media, Culture, Ex Vivo, Tissue And Cell (NDS, Class II) · First FDA decision Feb 16, 2001, newest Feb 16, 2001Infertility
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
3
Naming "Dulbecco's Modified Eagle"
MAUDE reports
0
Brand "Dulbecco's Modified Eagle", since 2015
PubMed studies
3,716
Mentioning "Dulbecco's Modified Eagle"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Dulbecco's Modified Eagle Medium (Dmem)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- DULBECCO'S MODIFIED EAGLE MEDIUM (DMEM)New device typeDe Novo
DEN000008 · Decided Feb 16, 2001 · 59 days after receipt
Device type: Media, Culture, Ex Vivo, Tissue And Cell (NDS) · GI, Urology & Nephrology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Dulbecco's Modified Eagle", any status and sponsor, newest update first.
Cellontech Co., Ltd.Not on our public-company list
NCT02539056 · 22 participants · Start Oct 15, 2012 · Primary completion Mar 18, 2016
Device: Chondron Implantation · For: Osteoarthritis; Traumatic Arthritis
Sites: Incheon, South Korea; Seoul, South Korea
Cellontech Co., Ltd.Not on our public-company list
NCT02539069 · 10 participants · Start Oct 23, 2012 · Primary completion Jan 15, 2016
Device: Chondron Implantation · For: Osteoarthritis; Traumatic Arthritis
Sites: Seoul, South Korea
- Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic AlopeciaStatus unknown
HistogenNot on our public-company list
NCT01501617 · 56 participants · Start Dec 2011 · Primary completion Jun 2012
Device: Dulbecco's Modified Eagle Medium, DMEM · For: Androgenetic Alopecia
Sites: Pasig, Philippines
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Dulbecco's Modified Eagle", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code NDS
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Dulbecco's Modified Eagle"[tiab]. The summary above synthesizes these.
- Stability and antioxidant capacity of epigallocatechin gallate in Dulbecco's modified eagle medium.
Wang M, Zhang H, Yi L, et al. · Food Chem · 2022
- Stability profiling and degradation products of dihydromyricetin in Dulbecco's modified eagle's medium.
Zhang HL, Wang ML, Yi LZ, et al. · Food Chem · 2022
- Adaptation of MC3T3 cell line to Dulbecco's Modified Eagle's medium.
Bahraminasab M, Arab S, Jahan A · Tissue Cell · 2020
- Aggregation of Thermoresponsive Polymethacrylates in a Dulbecco's Modified Eagle Medium and Its Salts.
Otulakowski , Trzebicka B · Polymers (Basel) · 2023
- Dulbecco's modified eagle's medium and minimum essential medium--which one is more preferred for establishment of Caco-2 cell monolayer model used in evaluation of drug absorption?
Wu XW, Wang RF, Yuan M, et al. · Pharmazie · 2013Research Support, Non-U.S. Gov't
- Dulbecco's Modified Eagle Medium is neuroprotective when compared to standard vitrectomy irrigation solution.
Schultheiss M, Januschowski K, Ruschenburg H, et al. · Graefes Arch Clin Exp Ophthalmol · 2013
- Normal Human Thyrocytes in Culture.
Morgan SJ, Neumann S, Gershengorn MC · Methods Mol Biol · 2018Research Support, N.I.H., Intramural
- Ethanolamine Is a New Anti-Prion Compound.
Uchiyama K, Hara H, Chida J, et al. · Int J Mol Sci · 2021
- A protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow.
Soleimani M, Nadri S · Nat Protoc · 2009Research Support, Non-U.S. Gov't
- Freezing and Thawing of Adipose-Derived Stromal/Stem Cells (ASCs).
Adam LT, Pepper MS, Ambele MA · Methods Mol Biol · 2025Research Support, Non-U.S. Gov't
- Comparison of the inactivation capacity of various UV wavelengths on SARS-CoV-2.
Matsuura R, Lo CW, Ogawa T, et al. · Biochem Biophys Rep · 2022
- Proliferative effects of nanobubbles on fibroblasts.
Heo H, Park J, Lee JI, et al. · Biomed Eng Lett · 2022
Other devices of this type
Also filed under product code NDS.
- Msc SfmYocon Biology Technology Company · 510(k) 2024
- MoFi Cell Culture Basal MediumDuogenic Stemcells Corporation · 510(k) 2024
- PRIME-XV FreezIS DMSO-Free MDFujifilm Irvine Scientific · 510(k) 2023
- Ct-StorEnergy Delivery Solutions · 510(k) 2021
- Optmizer Cts T-Cell Expansion Serum Free MediumLife Technologies, Inc. · 510(k) 2012
- Stempro Msc SfmLife Technologies Corporation · 510(k) 2011
- Knockout Sr Medium, Knockout Sr Xenofree Medium Model 10828, 12618Life Technologies Corporation · 510(k) 2010
- Aim-V (R) Medium, Model 087-0112Invitrogen Corporation · 510(k) 2002
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.